Galectin Therapeutics Inc. · NASDAQ:GALT
Galectin Therapeutics — PRO Pharmaceuticals — Investor Presentation (February 2008)
37 slides from Galectin Therapeutics's investor presentation, Feb 6, 2008
Slide 1: Pro-Pharmaceuticals, Inc. Advancing Drugs Through Glycoscience
P R O - P H A R M A C E U T I C A L S , I N C . Amex: P R W A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E® Exhibit 99.1
Slide 2: Forward Looking Statements
P R O - P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W Any statements in this presentation about future expectations, plans and prospects for the Company, including statements containing the words "believes," "anticipates," "pla
Slide 3: Mission
P R O - P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W Develop proprietary carbohydrate compounds with the potential to significantly improve treatments for cancer, liver, inflammatory and microbial diseases. This improvement is
Slide 4: Summary
P R O - P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W • Unique Technology – Multiple drug platforms • Positive pre-clinical and clinical trial results • Regulatory Strategy • Business Opportunities – Multi-billion dollar market
Slide 5: Technology
P R O - P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W 5 • Oncology • Fibrosis • Other opportunities Technology
Slide 6: Overview - Technology
P R O - P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W • Unique Technology – Drug design using carbohydrates – pending – Highly specific recognition mechanisms 6 Overview - Technology Five patents issued and eleven
Slide 7: Strong Intellectual Property Position
P R O - P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W • Composition of matter and field of use patents (5) – U.S. Pat 6,642,205 (11/04/03) – Methods and Compositions for Reducing side effects in Chemotherapeutic Treatments – U.
Slide 8: Composition of Matter and Methods of Delivery
P R O - P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W Methods and compositions for reducing toxicity of an existing chemotherapeutic drug by co-administering a polysaccharide UNIVERSAL CARBOHYDRATE LINKER TECHNOLOGY (UCLT™) enh
Slide 9: Strong Intellectual Property Position: 11 new patent applications filed
P R O - P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W 2 - enhanced treatment of cancer including reduced side effects 3 - delivery of anti-cancer drugs 1 - reducing side effects of chemotherapeutic treatments 1 - formulation fo
Slide 10: Lead Compound
P R O - P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W 10 LEAD COMPOUND
Slide 11: Targeting Lectins
P R O - P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W • Lectins are proteins that tightly bind certain carbohydrates • Galectins are a type of lectin that specifically bind galactose molecules • Galectin receptors are predomina
Slide 12: DAVANAT
P R O - P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W • Proprietary polysaccharide that targets Galectin receptors on cancer cells • Increases efficacy and decreases toxicity of chemotherapeutic agents • Currently in Phase ll t
Slide 13: Oncology Platform: CARBOSOME
P R O - P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W • DAVANAT ® selectively binds to lectin receptors on cancer cells • Once bound, the polymer releases its payload into the cancer cell 13 Oncology Platform: CARBOSOME™
Slide 14: Second Platform: Universal Carbohydrate Linker Technology
P R O - P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W • New chemical entity that contains a carbohydrate backbone 14 Second Platform: Universal Carbohydrate Linker Technology
Slide 15: Clinical Trial Results
P R O - P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W 15 CLINICAL TRIAL RESULTS
Slide 16: Pre-Clinical Results: Slowest Tumor Growth
P R O - P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W DAVANAT® mixed with Avastin® and with 5-FU showed best results – 16 Pre-Clinical Results SLOWEST TUMOR GROWTH Tumor Weight Gain in Mice Implanted with COLO 205, Human Colon
Slide 17: Pre-Clinical Results: Mice Show Healthy Weight Gain
P R O - P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W DAVANAT® mixed with Avastin and with 5-FU showed best results – 17 Pre-Clinical Results Mice Show Healthy Weight Gain Total Weight Gain of Mice Implanted with COLO 205, Huma
Slide 18: Pre-Clinical Results: Clinical Benefit Index
P R O - P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W DAVANAT® mixed with Avastin and with 5-FU showed best results – 18 Pre-Clinical Results Clinical Benefit Index = Lowest Toxicity and Best Efficacy
Slide 19: Clinical Trial Results
P R O - P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W DAVANAT® mixed with 5-FU eliminated the expected drop in blood levels from chemotherapy 19 AUC Hematocrit Hemoglobin Red blood cells White blood cells Platelets Clinical Tri
Slide 20: Clinical Trial Summary
P R O - P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W Results • 48 patients dosed with DAVANAT ® /5-FU in Phase l/ll, Line three and four clinical trials • Stabilized 43% of end stage patients with measurable disease: 2-13 mont
Slide 21: Beyond Oncology - New Platforms
P R O - P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W • Use Proprietary IP to Design New Drugs • Fibrosis – Multiple Indications • Anti-Microbial • Synthetic Statins (Cholesterol) 21 Beyond Oncology -New Platforms-
Slide 22: Fibrosis
P R O - P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W 22 FIBROSIS
Slide 23: Fibrosis - Background
P R O - P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W • Worldwide, 170 million people are infected with chronic hepatitis C • 10-40% of patients respond to current therapies (notably, removal of cause) – There are no effective
Slide 24: Mechanism of Action - Effect on Fibrotic Markers In-vitro
P R O - P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W Reduces the production of Collagen Collagen is central to fibrogenesis diseases and the scarring of organs. Reduces Expression of Matrix Metalloproteinase -2 (MMP-2) MMP-2 h
Slide 25: Rat Fibrosis Model Proof of Concept
P R O - P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W Reversal of Fibrosis with PRO–GR 300 after 4 weeks of treatment Liver Fibrosis, induced by injection of chemical toxin for 8 weeks 25 Rat Fibrosis Model Proof of Concept Pro
Slide 26: Other Fibrosis Applications
P R O - P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W • The same receptors influence many types of Fibrosis • Therefore PRO-GR 300 may be effective in different types of Fibrosis • Chemical toxicity, microbial infection & physi
Slide 27: Regulatory Strategy
P R O - P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W 27 Regulatory Strategy
Slide 28: Regulatory Strategy
P R O - P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W • Submit final report for completed Phase II end stage patient trial • Continue Phase II trials underway • Drug Master File (Mfg data) to FDA • Initiate IND for non-intraven
Slide 29: Product Development Pipeline Jan 2008
P R O - P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W PRODUCT INDICATION DISCOVERY PRE-CLINICAL PHASE 1 PHASE 2 DAVANAT ® / 5-FU line I DAVANAT ® / 5-FU/LV/ AVASTIN ® line I DAVANAT ® / 5-FU line IV PRO-GR 300 Biliary Cancer On
Slide 30: 2008 Milestones
P R O - P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W • Submit Drug Master File (DMF) - First Quarter • File Investigative New Drug (IND) Application: Triggers FDA Review of DMF - Second Quarter • DMF approval projected – Secon
Slide 31: Business Opportunities
P R O - P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W 31 Business Opportunities Several Multi-billion dollar markets can be addressed
Slide 32: Business Opportunities
P R O - P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W • Oncology – Excipient to 5-FU, improve results & reduce side effects – Eliminates/reduces need for additional drugs to treat side effects – Extend patent life of chemo drug
Slide 33: Business Opportunities
P R O - P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W • Fibrosis – Accelerate pre-clinical trials based on proven safety of carbohydrates and DAVANAT® • Liver • Kidney – File IND – Start clinical trials ASAP – Early partnership
Slide 34: Corporate
P R O - P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W 34 CORPORATE
Slide 35: Corporate Summary
P R O - P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W • PRW began operations in 2001 • Five U.S. patents issued • Capital raised: $39.5 million (cumulative) • Shares outstanding: 40.4 million (11/01/07) • Fully diluted: 52.1 mi
Slide 36: Management Team
P R O - P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W • David Platt, Ph.D., Chairman & Chief Executive Officer – Co-founder, co-developer of Glycoscience technology. Founder: SafeScience; developed anti-angiogenesis drug. U of
Slide 37: Summary
P R O - P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W • Proprietary Technology With Multiple Current and Future Applications • Excipient for Existing Chemotherapy Protocols • Reduces or Eliminates Adverse Side Effects and Lower
PRO Pharmaceuticals — Investor Presentation (February 2008) on 6ix